Juvenile Arthritis

April 05, 2021

This week, Rheumatology Network sat down with Daniel J. Lovell, MD, MPH, to discuss his study, “Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis.”

April 02, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 2, 2021.

March 29, 2021

Of the 26 autoimmune disease and related conditions studied, 14 (53.8%) had higher prevalence in the juvenile idiopathic arthritis (JIA) group when compared with the general pediatric (GP) population cohort.

October 22, 2020

Children who take oral corticosteroids for autoimmune conditions, such as juvenile arthritis, psoriasis, inflammatory bowel disease or other conditions, like asthma, have an increased risk of diabetes, high blood pressure, and blood clots, say researchers writing in the American Journal of Epidemiology.

October 05, 2020

In juvenile idiopathic arthritis, predictive genomic risk scores may enhance current diagnosis protocols, prioritizing higher-risk patients for follow-up and reducing treatment delays, according to a study published this month in Annals of Rheumatic Diseases.

September 30, 2020

Golimumab (Simponi Aria, Janssen/J&J) has been approved by the U.S. Food and Drug Administration for two pediatric conditions:active pediatric juvenile idiopathic arthritis (JIA) and active pediatric psoriatic arthritis.

September 30, 2020

The U.S. Food and Drug Administration has approved tofacitinib Xeljanz, Pfizer) for the treatment of children and adolescents two years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA).

July 14, 2020

The U.S. FDA has approved the first treatment for adult-onset Still's disease, a rare form of systemic juvenile idiopathic arthritis associated with high fever, arthritis and rash.

March 03, 2020

Tocilizumab might be a useful adjunctive therapeutic option for children with juvenile idiopathic arthritis-associated uveitis that doesn't respond to TNFi treatment, say researchers recently writing in The Lancet Rheumatology.

November 27, 2019

Children with inflammatory bowel disease, juvenile idiopathic arthritis, and chronic noninfectious osteomyelitis who were treated with TNF inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, say researchers recently writing in Arthritis Care & Research.